The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study.
about
The significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosisBlood-brain barrier breakdown in acute and chronic cerebrovascular diseaseMultiple sclerosis: the role of cytokines in pathogenesis and in therapiesThe challenges, advantages and future of phenome-wide association studiesMultiple sclerosis: molecular mechanisms and therapeutic opportunitiesThe gut-brain connection: triggering of brain autoimmune disease by commensal gut bacteriaProinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis.Critical data-based re-evaluation of minocycline as a putative specific microglia inhibitor.The history of the tetracyclines.Minocycline inhibits alkali burn-induced corneal neovascularization in miceDoxycycline-mediated effects on persistent symptoms and systemic cytokine responses post-neuroborreliosis: a randomized, prospective, cross-over study.Improving outcomes of neuroprotection by minocycline: guides from cell culture and intracerebral hemorrhage in miceModulation of cytokine and cytokine receptor/antagonist by treatment with doxycycline and tetracycline in patients with dengue feverGlatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot studyUse of minocycline in viral infectionsProspects for minocycline neuroprotection.Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis.Novel Antiplatelet Activity of Minocycline Involves Inhibition of MLK3-p38 Mitogen Activated Protein Kinase Axis.Minocycline: far beyond an antibiotic.Biotic acts of antibiotics11C-(R)-PK11195 PET imaging of microglial activation and response to minocycline in zymosan-treated rats.Serum levels of matrix metalloproteinases: implications in clinical neurology.Tetracyclines and neuromuscular disorders.Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers.Nicotinic acid-mediated activation of both membrane and nuclear receptors towards therapeutic glucocorticoid mimetics for treating multiple sclerosis.Proteomic analysis of the anti-inflammatory action of minocycline.Involvement of Host Defense Mechanisms against Toxoplasma gondii Infection in Anhedonic and Despair-Like Behaviors in MiceDisruption of the serotonergic system after neonatal hypoxia-ischemia in a rodent model.Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial).Staphylococcus aureus harbouring Enterotoxin A as a possible risk factor for multiple sclerosis exacerbations.Minocycline suppresses experimental autoimmune encephalomyelitis by increasing tissue inhibitors of metalloproteinases.A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression.Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.Impact of Minocycline on Extracellular Matrix Metalloproteinase Inducer, a Factor Implicated in Multiple Sclerosis Immunopathogenesis.Minocycline protects oligodendroglial precursor cells against injury caused by oxygen-glucose deprivation.
P2860
Q27009126-35B523C3-4D11-4CAB-B1D4-A3F964F50120Q27010013-3EE1BFBB-C057-4E17-AD84-69F15E2232DFQ27011014-5E93A497-A8C4-4D95-B764-4CA9F86DF2C2Q27023725-B454418D-450F-46CA-A483-63878C634ED7Q27023735-5C4760E6-49E9-4327-8861-D701CC0EC0F1Q28078888-F342FE0F-5B89-4D7F-BC99-4496FF1E9C31Q29619978-0958DE15-D8A3-4D54-9FFB-B03D8D60D533Q31104505-48884D38-3AF8-450D-B875-B6CA98E5EB6BQ34242314-054AF9EC-1CC0-4A35-8F9E-3965EFCD0028Q34359185-A534A839-10C1-4FAE-8C5C-73CBCA2144F6Q34372745-1951C7DF-CF3A-4280-9923-DAF185C9D64FQ34659673-A62B5FC9-A86F-403E-AFFA-CBFDC2CF3925Q34726827-ED5675FA-FB3E-4C24-B97D-C42E7E51CBE6Q35004773-1DCCE220-D0BD-492B-ADE6-C5B9EC0E32B2Q35052651-2059E069-D191-4442-9CD4-1337BE0EF6DCQ35062807-5602F07B-8DC0-4C4F-8841-E04534F992EEQ35079515-A387B06E-E3B7-43C1-A070-688CCF11318FQ35589934-1A1F1A4C-33AE-4843-B89F-F6E1A6CB7332Q35606563-D1C6513D-C709-4C7B-87C6-D4D4C4AF2340Q36043123-ED2E7411-C300-4DF6-A4CF-128E7973BB3BQ36836358-54C35086-F193-4CED-9BB6-2843A8C327DDQ37101851-A8EDAF05-3ED7-4ECD-AA16-41B0E1AE6371Q37144048-D8B095A9-5CBD-4B1E-AE1B-8A14706655B5Q37977361-00513CA7-14F2-4758-B82E-21387D494D3DQ38064452-277806E8-F042-45FA-A863-C9CC1BC1420CQ38870841-B818219F-6DCF-46AD-B240-B3A5A12D171EQ39303280-C80B5EEE-2BB3-4E09-A628-D0ADD6C13493Q39616576-8B8CDAC7-13C6-4316-B40D-0F0F54456FCCQ40352700-6A6DAD60-B86A-465A-B661-67C0DFAF004FQ42577426-14F50A97-9260-440F-B385-EEC693B68739Q43219125-19EADD4C-07E8-4839-8CF8-82D9BC3944FBQ43416735-F4E1AAE0-0776-4D8E-9CBD-6136099822F6Q44327938-8CE7278F-B7EC-4436-A7D1-BE15DD569773Q47861374-E5988050-AED6-4ACE-9C18-67D1E9A67125Q48132175-8881F3BD-B684-47E2-9F5A-487C9167D465Q48305463-A884510E-F318-4065-AA0D-26B7B20ED882Q48709156-985BD0F4-D9B5-4325-BC7D-26989AD21E25
P2860
The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study.
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The clinical response to minoc ...... immune changes: a pilot study.
@ast
The clinical response to minoc ...... immune changes: a pilot study.
@en
The clinical response to minoc ...... immune changes: a pilot study.
@nl
type
label
The clinical response to minoc ...... immune changes: a pilot study.
@ast
The clinical response to minoc ...... immune changes: a pilot study.
@en
The clinical response to minoc ...... immune changes: a pilot study.
@nl
prefLabel
The clinical response to minoc ...... immune changes: a pilot study.
@ast
The clinical response to minoc ...... immune changes: a pilot study.
@en
The clinical response to minoc ...... immune changes: a pilot study.
@nl
P2093
P2860
P356
P1476
The clinical response to minoc ...... immune changes: a pilot study.
@en
P2093
Mitchell JR
Todoruk TR
P2860
P304
P356
10.1177/1352458506070319
P577
2007-02-09T00:00:00Z